Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
Zacks News
Amgen (AMGN) Q2 Earnings & Sales Beat, New Drugs Shine
by Zacks Equity Research
Amgen (AMGN) beats estimates for earnings and sales in the second quarter. Higher demand for new growth drivers was offset by the erosion of mature brands from brand/biosimilar competition.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $7.91 in the latest trading session, marking a +0.64% move from the prior day.
Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up
by Zacks Equity Research
Eli Lilly's (LLY) Q2 earnings beat estimates while sales miss. New drugs drive sales despite generic competition to key drug Cialis.
Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer
by Zacks Equity Research
Mylan (MYL) gains from merger deal with a Pfizer unit and tops on earnings and sales in Q2.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $7.68, moving -0.13% from the previous trading session.
3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
by Kinjel Shah
Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.
Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.11 in the latest trading session, marking a -1.1% move from the prior day.
Teva Shares Fall Further as Morgan Stanley Downgrades Rating
by Zacks Equity Research
Shares of Teva (TEVA) are on a downtrend on the risk of high litigation costs related to opioid epidemic in the United States. Morgan Stanley downgrades its rating on Teva.
J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.
Amneal (AMRX) Down on Guidance Update & Restructuring Plan
by Zacks Equity Research
Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.
Court Ruling Topples Trump Order, No Price Display in TV Ads
by Zacks Equity Research
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset
by Zacks Equity Research
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $9.43 in the latest trading session, marking a +1.18% move from the prior day.
Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer
by Zacks Equity Research
Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.
AstraZeneca Gets CHMP Nod for Forxiga/Fasenra Expanded Label
by Zacks Equity Research
AstraZeneca (AZN) gets positive CHMP opinion for self-administration option for Fasenra and the Fasenra pen and to include outcomes data on Forxiga???s label.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.89 in the latest trading session, marking a +0.91% move from the prior day.
Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids
by Zacks Equity Research
Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.12 in the latest trading session, marking a -0.73% move from the prior day.
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.62 in the latest trading session, marking a -1.03% move from the prior day.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $9.26 in the latest trading session, marking a -1.59% move from the prior day.
Celgene's Filing for Ozanimod Accepted for Review in US/EU
by Zacks Equity Research
The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.
Lilly's Emgality Gets FDA Approval for Cluster Headache
by Zacks Equity Research
Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.
Biogen Reports Interim Phase III Data on Diroximel Fumarate
by Zacks Equity Research
Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate
by Zacks Equity Research
Lilly (LLY) inks a deal with the privately held Centrexion Therapeutics to add the latter's early-stage pain candidate, CNTX-0290, to its portfolio.